GlycoMimetics (GLYC) paused their deal late last year when the terms were $14 to $16/share with 4M shares offered. This week they are back with a short marketing duration and a lower price of $8/share and 5.7M shares offered plus the typical 15% over allotment.
Insiders including Pfizer (PFE) have agreed to buy $14M of stock in the IPO. The deal is being brought by an odd group of banks led by Jefferies and Barclays. The lower price and insider commitments should help the deal get done this time.
Sickle Cell is an orphan disease category and . . .